Home >  Dermatology >  Dermatology News >  Compared to Dupilumab...

Compared to Dupilumab Upadacitinib rapidly improves itching and clears skin in atopic dermatitis: JAMA

Written By :  Dr Manoj Kumar Nayak
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-08-09 03:30 GMT   |   Update On 2023-10-19 10:20 GMT
Advertisement

Upadacitinib vs Dupilumab in adult atopic dermatitis (AD) : JAMA study

Atopic dermatitis is a severely pruritic relapsing disorder with multiple cytokines like interleukins (IL) like IL- 4, 13, 22,-31, interferon gamma (IFN-γ) and thymic stromal lymphopoietin (TSLP) involved in its pathogenesis. Dupilumab, a monoclonal antibody against α-subunit of IL-4 and IL-13 receptors is approved for the treatment of moderate-to-severe AD. Upadacitinib is an oral, reversible, selective JAK1 inhibitor recently showing evidence of efficacy in AD.2

The present study was a head-to-head, multicenter, randomized, double-blinded, double dummy, active-controlled 24-week clinical trial conducted from February 21, 2019, to December 9, 2020 comparing the safety and efficacy of upadacitinib vs dupilumab in adults with moderate-to-severe AD. Eligible patients diagnosed with moderate to severe AD requiring systemic therapy were recruited.

Criteria for moderate to severe disease was defined as either one or all of the following-≥

Advertisement
  • 10% of body surface area affected
  • Eczema Area and Severity Index [EASI] ≥16
  • validated Investigator's Global Assessment for AD score ≥3
  • weekly average Worst Pruritus Numerical Rating Scale [NRS] score ≥4
  • Patients were randomized into 2 groups to receive 30 mg of upadacitinib once daily till week 24 or 300mg of dupilumab every 2weeks after a loading dose of 600mg, starting at week 2 and until week 22. The primary end points were fixed at 75% improvement in EASI (EASI75) at week 16. Secondary end points were fixed as:
  • percentage change from baseline in Worst Pruritus NRS in total, at week 1 and at week 4
  • Worst Pruritus NRS improvement of 4 points or more at week 16
  • achievement of EASI100 and EASI90 at week 16
  • achievement of EASI75 at week 2
  • Efficacy analyses were conducted in the intent-to-treat population.Of 924 patients screened, 692 were enrolled and treated, 348 received upadacitinib and 344 received dupilumab. Most patients completed 16 weeks of treatment. Demographic and baseline characteristics were balanced among the upadacitinib and dupilumab groups. At week 16, 247 patients receiving upadacitinib (71.0%) and 210 patients receiving dupilumab (61.1%) achieved EASI75 (P = .006). All secondary end points demonstrated the superiority of upadacitinib over dupilumab including improvement in Worst Pruritus NRS as early as week 1 (31.4% [1.7%] vs 8.8% [1.8%]; P < .001), achievement of EASI75 at week 2 (152 [43.7%] vs 60 [17.4%]; P < .001), and achievement of EASI100 at week 16 (97 [27.9%] vs 26 [7.6%]; P < .001). Acne was the most common (55 [15.8%]) AE reported with upadacitinib. Rates of serious infection, eczema herpeticum, herpes zoster, and laboratory-related adverse events were higher for patients who received upadacitinib. Rates of conjunctivitis and injection-site reactions were higher for patients who received dupilumab.

    In conclusion this is the first study directly comparing upadacitinib with dupilumab for AD demonstrating superior efficacy, rapidity of onset of action and higher skin clearance and itch relief of upadacitinib over dupilumab.

    Source-

  • Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021 Aug 4. doi: 10.1001/jamadermatol.2021.3023. Epub ahead of print. PMID: 34347860.
  • Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877-884. doi:10.1016/j.jaci.2019.11.025


Tags:    
Article Source : Journal of the American Medical Association Dermatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Manoj Kumar Nayak

Dr Manoj Kumar Nayak has completed his M.B.B.S. from the prestigious institute Bangalore medical college and research institute, Bengaluru. He completed his M.D. Dermatology from AIIMS Rishikesh. He is actively involved in the field of dermatology with special interests in vitiligo, immunobullous disorders, psoriasis and procedural dermatology. His continued interest in academics and recent developments serves as an inspiration to work with medical dialogues.He can be contacted at editorial@medicaldialogues.in.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Sulfhydryl-Containing Foods and Drugs Linked to Pemphigus Vulgaris Risk: Study

Early Emollient Use Reduces Risk of Atopic Dermatitis in Infants: JAMA

The Minds Behind IJDVL: Conversations with Dr. Archana Singal, Dr. Geeti Khullar, Dr. Pooja Arora & Dr. Sunny Duttagupta

FDA Approves Delgocitinib Cream for Chronic Hand Eczema

Smoking Significantly Increases Psoriasis Relapse Risk, reveals research

Journal Club: JCAS Unplugged- Conversations with the Minds Shaping Cutaneous & Aesthetic Sciences, Ft.Prof Dr Sandeep Arora, Editor-in-Chief & Dr Sunny Duttagupta, Director Publishing, Scientific Scholar

Severe Atopic Dermatitis Linked to Increased Risk of Ischemic Stroke, Finds Meta-Analysis

Biocon Biologics launches Nepexto in Australia